Russell Frank Company’s Travere Therapeutics TVTX Stock Holding History

Russell Frank Company’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$256K	Buy	18,720 +8,684	+87%	+$132K	﹤0.01%	2628
2015 Q4	$198K	Sell	10,036 -16,368	-62%	-$327K	﹤0.01%	2694
2015 Q3	$535K	Sell	26,404 -34,594	-57%	-$1.02M	﹤0.01%	2451
2015 Q2	$2.02M	Buy	+60,998	New	+$1.67M	﹤0.01%	1964
2014 Q2	–	Sell	-24,200	Closed	-$341K	–	2851
2014 Q1	$341K	Buy	+24,200	New	+$372K	﹤0.01%	2484

Other funds holding TVTX

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

LOAMU

Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Russell Frank Company's TVTX Position: Q1 2016 in Review

Russell Frank Company increased its Travere Therapeutics (TVTX) stake by 87% in Q1 2016, buying an estimated $132K and bringing the position to 18,720 shares worth $256K. The position accounts for ﹤0.01% of the portfolio, ranked #2628.

Russell Frank Company first reported a position in TVTX in Q1 2014 and has held it in 5 quarters since. The position peaked at $2.02M in Q2 2015. 119 funds tracked by Wall St. Rank hold TVTX as of Q1 2016.

Russell Frank Company held 18,720 shares of Travere Therapeutics worth $256K as of Q1 2016.
Russell Frank Company bought 8,684 Travere Therapeutics shares in Q1 2016, an estimated $132K.
Travere Therapeutics made up ﹤0.01% of Russell Frank Company's portfolio in Q1 2016, its #2628 holding.
Russell Frank Company first reported a position in Travere Therapeutics in Q1 2014 and has held it in 5 quarters since.
Russell Frank Company's Travere Therapeutics position peaked at $2.02M in Q2 2015.
119 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.